Use of the Gail Model and Breast Cancer Preventive Therapy among Three Primary Care Specialties

Journal of Women's Health

Volumn 23, Issue 9, 2014, Pages 746-752

  Corbelli, Jennifer ^a   Borrero, Sonya ^a,b   Bonnema, Rachel ^c   McNamara, Megan ^d,e   Kraemer, Kevin ^a   Rubio, Doris ^a   Karpov, Irina ^a   McNeil, Melissa ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VA Pittsburgh Healthcare System   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Louis Stokes Cleveland VA Medical Cente   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; GYNECOLOGIST; HEALTH SURVEY; HUMAN; INTERNIST; MALE; MEDICAL SPECIALIST; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; BREAST NEOPLASMS; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; GENERAL PRACTICE; GYNECOLOGY; INTERNAL MEDICINE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROCEDURES; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; BREAST NEOPLASMS; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; ESTROGEN RECEPTOR MODULATORS; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; GYNECOLOGY; HUMANS; INTERNAL MEDICINE; LOGISTIC MODELS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 84920819415     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4742     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;621:10-29.
2. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:727-737, W237-242.
3. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:99-119.
4. American College of Obstetricians and Gynecologists. Practice bulletin No. 122: Breast cancer screening. Obstet Gynecol 2011;118:372-382.
5. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
6. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-1548.
7. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.
8. Adams-Campbell LL, Makambi KH, Palmer JR, et al. Diagnostic accuracy of the Gail model in the Black Women's Health Study. Breast J 2007;13:332-336.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
10. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
11. Nelson HD, Smith ME, Griffin JC, et al. Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:604-614.
12. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-134.
13. Sabatino SA, McCarthy EP, Phillips RS, et al. Breast cancer risk assessment and management in primary care: Provider attitudes, practices, and barriers. Cancer Detect Prev 2007;31:375-383.
14. Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-585.
15. Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-446.
16. Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-880.
17. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29:2327-2333.
18. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:2942-2962.
19. National Survey of Primary Care Physicians'Recommendations and Practice for Breast, Cervical, Colorectal, and Lung Cancer Screening. Bethesda, MD: National Cancer Institute 2010. Available at healthservices.cancer.gov/surveys/screening-rp Accessed January 12, 2014.
20. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
21. Dugdale DC, Epstein R, Pantilat SZ. Time and the patientphysician relationship. J Gen Intern Med 1999;14:S34-40.
22. Yarnall KS, Pollak KI, Ostbye T, et al. Primary care: Is there enough time for prevention? Am J Public Health 2003;93:635-641.
23. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532.
24. Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-2265.
25. Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: A summary of the evidence for the U.S. Preventive Services Task Force. Ann InternMed 2002;137:59-69.
26. Heisey R, Pimlott N, Clemons M, et al. Women's views on chemoprevention of breast cancer: Qualitative study. Can Fam Physician 2006;52:624-625.
27. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet 2013;381:1827-1834.
28. Noah-Vanhoucke J, Green LE, Dinh TA, et al. Costeffectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer 2011;117:3322-3331.
29. Pearce KA, Furberg CD, Psaty BM, et al. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 1998;11:618-629.
30. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD001155.
31. Friedman L, Cooper HP, Webb JA, et al. Primary care physicians' attitudes and practices regarding cancer genetics: A comparison of 2001 with 1996 survey results. J Cancer Educ 2003;18:91-94.
32. Friedman LC, Plon SE, Cooper HP, et al. Cancer genetics-Survey of primary care physicians' attitudes and practices. J Cancer Educ 1997;12:199-203.
33. Haas JS, Kaplan CP, Gregorich SE, et al. Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? J Gen Intern Med 2004;19:302-309.
34. Kaplan CP, Haas JS, Perez-Stable EJ, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41(1):7-15.
35. Mouchawar J, Klein CE, Mullineaux L. Colorado family physicians' knowledge of hereditary breast cancer and related practice. J Cancer Educ 2001;16:33-37.
36. Santora LM, Mahoney MC, Lawvere S, et al. Breast cancer screening beliefs by practice location. BMC Public Health 2003;3:9.
37. United States Census Bureau. State and County QuickFacts: Pittsburgh, Pennsylvania. Available at http://quickfacts.census .gov/qfd/states/42/4261000.html Accessed May 12, 2014.
38. United States Census Bureau. American FactFinder. Health insurance coverage status: 2012 American community survey 1-year estimates. Available at http://factfinder2.census.gov/faces/ tableservices/jsf/pages/productview.xhtml?pid =ACS-12-1YR-S2701&prodType = table Accessed May 12, 2014.
39. Brener ND, McManus T, Galuska DA, et al. Reliability and validity of self-reported height and weight among high school students. J Adolescent Health 2003;32:281-287.
40. Bender BG, Bartlett SJ, Rand CS, et al. Impact of interview mode on accuracy of child and parent report of adherence with asthma-controller medication. Pediatrics 2007;120: e471-477.
41. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337-347.